SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

OCC Orthocell Limited

Healthcare · Biotechnology · website
$0.76
52wk 0.67 – 1.58
Overall
64.2
Value
67.6
Growth
100.0
Health
100.0
Quality
0.0
Momentum
28.5
Dividend
—
Price
About Orthocell Limited

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; OrthoATI, for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair. The company also develops Collagen Medical Device platform products for bone, nerve, tendon, muscle, or scar tissue, and ligament repair; and Tendon Cell Therapy for rotator cuff and lateral epicondyle indications. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.

Price analytics

Returns

1 day -0.7%
1 week 2.7%
1 month 4.8%
3 months -12.6%
6 months -7.3%
1 year -47.9%
3 years 117.1%

Risk

Volatility (1y ann.) 55.1%
Beta vs ASX 200 1.08
Sharpe (1y) -0.99
VaR 95% (1-day) -5.0%
Max drawdown (1y) -54.9%
Off 1-year high -50.3%

Technicals

RSI(14) 58
vs 50DMA 2.0%
vs 200DMA -9.0%
Trend Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 67.6
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
27
Price / Sales
0
Growth 100.0
Revenue growth (1y)
100
Revenue CAGR (3y)
100
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health 100.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
100
Debt / Equity
100
Quality (Profitability & Cash Flow) 0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 28.5
6-month return vs ASX 200
27
Price vs 200-day average
20
Price vs 50-day average
60
Position in 52-week range
10

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$207.02M
P/E (trailing)
—
P/E (forward)
-50.67
EPS (trailing)
-0.05
Dividend yield
—
Payout ratio
0.0%
Beta
-0.06
EV / EBITDA
-9.23
Price / Book
6.03
ROE
-56.8%
Operating margin
-159.8%
Net margin
-122.0%
Total cash
$43.95M
Total debt
$970,192
Current ratio
5.97
Debt / Equity
0.03
Free cash flow
$-9.81M
Avg volume
298,087
Latest annual results (FY ending 30 Jun 2026)
  • Revenue$11.41M
  • Gross profit$11.41M
  • Operating income-$19.10M
  • Net income-$13.91M
  • Diluted EPS-0.05
  • Free cash flow-$14.01M
  • Net debt-$42.98M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4